Donald R. Dye

Donald R. Dye has a diverse work experience, starting with their role as a Managing Partner at Poder Partners since October 2022. Donald R. is also an Investor and Advisor at Koning Corporation since August 2022. Donald co-founded and advises Tarus Therapeutics, a biotechnology company, since August 2019. Donald R. is also a Co-Founder and Advisor at LeviSense Medical, Inc. since June 2017. Donald has been a Member of the Board of Trustees and Treasurer at amfAR, The Foundation for AIDS Research since November 2019. Donald R. is an Early Investor at Akston Biosciences Corporation since April 2021. Additionally, Donald is an Early Investor at Tvardi Therapeutics, a clinical stage biotechnology company, since April 2021. Donald R. also serves as an Early Investor at Etiometry Inc., a leader in clinical decision-support software for the intensive care environment, since May 2017. Donald is a Seed Investor and Advisor at Prospective Research, Inc., a company focused on feed-incorporated preventative disease management solutions for the aquaculture industry, since March 2017. Lastly, they are a Board Member at Luciole Pharmaceuticals, Inc., which uses conventional lab work and artificial intelligence to identify small molecules for neurodegenerative diseases, since July 2021 until March 2023.

Donald R. Dye has pursued various educational opportunities throughout their career. Donald R. obtained an MBA with a focus on Finance from Northwestern University - Kellogg School of Management. Donald R. also obtained a Language Certificate in Mandarin from Beijing Language and Culture University. Additionally, they completed a Bachelor's degree in Economics with minors in Biochemistry and Chinese from Occidental College. Donald also holds a Language Certificate in German from the University of Zurich.

In terms of certifications, Donald received professional training in various fields. Donald R. obtained a certification in IMMUNO ONCOLOGY AND PRECISION ONCOLOGY from Harvard Medical School in June 2020. In November 2018, they completed a certification course on ARTIFICIAL INTELLIGENCE, MACHINE LEARNING AND PREDICTIVE ANALYTICS from the Massachusetts Institute of Technology. Donald also obtained a Board Director Certification from the National Association of Corporate Directors (NACD) in March 2018, and a Sarbanes Oxley Certification from Illumeo in January 2018.